Neutralizing anti-IFN-beta antibodies: how much more evidence do we need to use them in practice?

@article{Giovannoni2005NeutralizingAA,
  title={Neutralizing anti-IFN-beta antibodies: how much more evidence do we need to use them in practice?},
  author={Gavin Giovannoni and Andrew M. Goodman},
  journal={Neurology},
  year={2005},
  volume={65 1},
  pages={6-8}
}

• Gavin Giovannoni, Andrew M. Goodman
• Published 2005 in Neurology

Neutralizing antibodies (NAbs) are a major hurdle to the successful use of biologics in clinical practice. The impact of NAbs is obvious in biologic systems with no redundancy. NAbs induced in response to treatment with recombinant erythropoietin or thrombopoietin cause life-threatening complications of pure red cell aplasia and thrombocytopenia as a direct… CONTINUE READING

Save

Watch Paper

Cite

View PDF